Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inotiv, Inc. (NASDAQ: NOTV) SEC filings page on Stock Titan provides centralized access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted summaries to help interpret key points. Inotiv is a contract research organization offering nonclinical and analytical drug discovery and development services and research models and related products and services, and its filings offer detailed insight into how this business operates and evolves.
Through periodic and current reports, investors can review how Inotiv reports performance in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, including revenue drivers such as safety assessment services, general toxicology, biotherapeutic analysis, discovery and translational sciences services, and non-human primate product and service revenues. Annual and quarterly reports (such as Forms 10-K and 10-Q, when available) typically include segment discussions, risk factors, liquidity and capital resources, and descriptions of non-GAAP measures like Adjusted EBITDA that the company uses to evaluate its operations.
Current reports on Form 8-K, several of which are reflected in the recent data, highlight material events such as preliminary financial results, corrections to earnings releases, cybersecurity incidents, and legal and regulatory developments. Examples include disclosures about a cybersecurity incident affecting certain systems and data, proposed settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and engagement of financial advisors to explore potential debt refinancing alternatives.
Stock Titan’s interface is designed to surface these filings in real time as they are posted to EDGAR, while AI-generated explanations can help clarify complex sections, such as litigation descriptions, settlement terms, governance commitments, and capital structure updates. Users can also review insider and executive-related filings, such as Forms 3, 4, and 5 when available, to understand equity transactions by officers and directors.
By using the NOTV SEC filings page, investors and researchers can quickly locate Inotiv’s official regulatory communications and rely on AI tools to interpret how reported financial results, risk disclosures, legal matters, and strategic initiatives relate to the company’s nonclinical and research model-focused business.
Inotiv, Inc. (NOTV) director R. Matthew Neff sold 2,000 shares of common stock on 09/02/2025 under a pre-established Rule 10b5-1 trading plan. The reported weighted average sale price was $1.6688 per share, with individual sale prices ranging from $1.6550 to $1.6900. After the transactions, Neff beneficially owns 147,102 shares. The Form 4 was signed by Beth Taylor as attorney-in-fact on 09/04/2025 and includes an undertaking to provide per-price sale detail to regulators or holders upon request.
Inotiv, Inc. (NOTV) Form 144 reports a proposed sale of 6,000 common shares through The Charles Schwab Corporation with an aggregate market value of $10,000. The filing lists 34,354,251 shares outstanding and an approximate sale date of 09/02/2025. The shares were acquired as restricted stock that vested on 04/01/2023. The filing also discloses prior sales by the same person of 2,000 shares on 07/01/2025 (gross proceeds $3,620) and 2,000 shares on 08/01/2025 (gross proceeds $3,818). The signer represents they have no undisclosed material nonpublic information.
Inotiv, Inc. (NASDAQ: NOTV) is filing an S-3 shelf prospectus to permit future offerings of securities, including an at-the-market equity program managed by Jefferies. The company describes two operating segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS), which together provide nonclinical drug development services and research animals/products to pharmaceutical, device, academic and government clients. The prospectus states net proceeds are expected to be used for working capital and general corporate purposes, and sales may occur from time to time at varying prices under a sales agreement with Jefferies that pays up to 3.0% commission. The registrant discloses an auditor’s report from Ernst & Young LLP that includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern and notes material weaknesses in internal control over financial reporting. The filing warns investors of immediate dilution risk, variability of proceeds from ATM sales, and typical forward-looking statement cautions.
Inotiv, Inc. reported that on August 8, 2025 it discovered a cybersecurity incident in which a threat actor gained unauthorized access to and encrypted certain company systems. In response, Inotiv launched an investigation, engaged external cybersecurity specialists, restricted access to affected systems, and notified law enforcement.
The incident has disrupted parts of Inotiv’s business operations by limiting access to portions of its networks, internal data storage, and some internal business applications. The company has activated its business continuity plan, shifting some work to offline alternatives while it works to restore systems, though the timeline for full restoration is not yet known. The investigation is ongoing, and Inotiv states that the full scope, nature, and operational and financial impacts are not yet known, and it has not determined whether the incident is reasonably likely to have a material impact.